Publications by authors named "Satoe Kawakami"
Purpose: We compared overall survival (OS) in patients with human epidermal growth factor receptor 2 ()-amplified, treatment-refractory metastatic colorectal cancer (mCRC) receiving pertuzumab plus trastuzumab (PER-HER) in the phase IIa MyPathway multibasket study (ClinicalTrials.gov identifier: NCT02091141) with OS in those receiving routine clinical care in an electronic health record-derived external control arm.
Methods: A noninterventional study was conducted using patient-level data from MyPathway participants receiving PER-HER and real-world patients with -amplified treatment-refractory mCRC receiving routine clinical care.
Aim: The phase II/III GATSBY study (NCT01641939) showed that trastuzumab emtansine did not have an efficacy benefit over taxane in patients with previously treated, human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic gastric or gastroesophageal junction cancer. We evaluated patients from Japanese centers within GATSBY.
Methods: In stage one, patients (randomized 2:2:1) received trastuzumab emtansine 3.
Article Synopsis
- - The phase III JACOB trial assessed the effectiveness and safety of adding pertuzumab to trastuzumab and chemotherapy compared to a placebo in Japanese patients with untreated HER2-positive metastatic gastric or gastroesophageal junction cancer.
- - In the study, 40 Japanese patients were randomized, showing that the pertuzumab group had a median overall survival of 22 months and a median progression-free survival of 12.4 months, outperforming the placebo group's 15.6 months and 6.3 months, respectively.
- - Although pertuzumab showed promising results in terms of survival, it also presented a higher frequency of serious adverse events, indicating the need for further research on new treatments for gastric cancer in this population.